MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRT-2359’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRT-2359 overview
MRT-2359 is under development for the treatment of solid tumors including small-cell lung cancer, non-small cell lung cancer, diffuse large B-cell lymphoma, multiple myeloma (Kahler disease), neuroendocrine cancer including prostate cancer, bladder cancer, HER2- breast cancer. The drug candidate is a molecular glue degrader selectively targeting GSPT1. It is administered orally and is being developed based on Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform.
Monte Rosa Therapeutics overview
Monte Rosa Therapeutics is a biotechnology company developing small molecules to degrade disease-related proteins. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of MRT-2359’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
